Tandem Diabetes Care (TNDM) EBIAT (2016 - 2025)
Tandem Diabetes Care's EBIAT history spans 13 years, with the latest figure at -$589000.0 for Q4 2025.
- For Q4 2025, EBIAT fell 178.01% year-over-year to -$589000.0; the TTM value through Dec 2025 reached -$204.7 million, down 113.18%, while the annual FY2025 figure was -$204.7 million, 113.18% down from the prior year.
- EBIAT reached -$589000.0 in Q4 2025 per TNDM's latest filing, up from -$21.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $10.8 million in Q4 2021 to a low of -$130.6 million in Q1 2025.
- Average EBIAT over 5 years is -$30.1 million, with a median of -$22.2 million recorded in 2024.
- Peak YoY movement for EBIAT: skyrocketed 161.59% in 2021, then tumbled 945.18% in 2022.
- A 5-year view of EBIAT shows it stood at $10.8 million in 2021, then plummeted by 246.67% to -$15.9 million in 2022, then plummeted by 89.26% to -$30.0 million in 2023, then surged by 102.52% to $755000.0 in 2024, then tumbled by 178.01% to -$589000.0 in 2025.
- Per Business Quant, the three most recent readings for TNDM's EBIAT are -$589000.0 (Q4 2025), -$21.2 million (Q3 2025), and -$52.4 million (Q2 2025).